Aflibercept news from FierceBiotech
NewsAflibercept misses endpoint in mid-stage study
Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a Read more...
European pipeline likely to stay thin to 2009
GlaxoSmithKline appears to be best situated among the European pharma companies to weather the drought Read more...
| Press ReleasesPRESS RLEASE: Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis TARRYTOWN, N.Y. -- Aug 23, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets